Overview

Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead...

Open

$0.00

Prior close

$245.51

Today's high

$0.00

Today's low

$0.00

52 Week high

$495.55

52 Week low

$197.81

News

Seeking Alpha • 1 day ago • ALNY

Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control Transcript

The Motley Fool • 4 days ago • ALNY

Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture

Seeking Alpha • 10 days ago • ALNY

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Business Wire • 16 days ago • ALNY

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Zacks Investment Research • 17 days ago • ALNY

4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects